AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2014
Dec 5, 2014
30583_dirs_2014-12-05_e1a50405-31ba-4fec-b2c3-604d140521a9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2014-12-03
Reporting Person: Ajer Jeffrey Robert (SVP, Chief Commercial Of)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-12-03 | Common Stock | M | 12000 | $38.59 | Acquired | 43590 | Direct |
| 2014-12-03 | Common Stock | S | 12000 | $91.0134 | Disposed | 31590 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-12-03 | Stock Option (right to buy Common Stock) | $38.59 | M | 12000 | Disposed | 2018-05-21 | Common Stock (12000) | Direct |
Footnotes
F1: The price in column 4 is a weight average price. The price actually received ranged from $91.00 to $91.12. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Original option grant vests 6/48th on 11/22/2008, and 1/48th on the 22nd day of every month thereafter.
F3: Reflects the number of stock options outstanding after the transaction from this specific stock option grant